Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission via induction of actin bundles

Reviewer #1 (Public Review):

Summary:

SARS-CoV-2 infection induces syncytia formation, which promotes viral transmission. In this paper, the authors aimed to understand how host-derived inflammatory cytokines IL-1α/β combat SARS-CoV-2 infection.

Strengths:

First, they used a cell-cell fusion assay developed previously to identify IL-1α/β as the cytokines that inhibit syncytia formation. They co-cultured cells expressing the spike protein and cells expressing ACE2 and found that IL-1β treatment decreased syncytia formation and S2' cleavage.

Second, they investigated the IL-1 signaling pathway in detail, using knockouts or pharmacological perturbation to understand the signaling proteins responsible for blocking cell fusion. They found that IL-1 prevents cell-cell fusion through MyD88/IRAK/TRAF6 but not TAK1/IKK/NF-κB, as only knocking out MyD88/IRAK/TRAF6 eliminates the inhibitory effect on cell-cell fusion in response to IL-1β. This revealed that the inhibition of cell fusion did not require a transcriptional response and was mediated by IL-1R proximal signaling effectors.

Third, the authors identified RhoA/ROCK activation by IL-1 as the basis for this inhibition of cell fusion. By visualizing a RhoA biosensor and actin, they found a redistribution of RhoA to the cell periphery and cell-cell junctions after IL-1 stimulation. This triggered the formation of actin bundles at cell-cell junctions, preventing fusion and syncytia formation. The authors confirmed this molecular mechanism by using constitutively active RhoA and an inhibitor of ROCK.

Diverse Cell types and in vivo models were used, and consistent results were shown across diverse models. These results were convincing and well-presented.

Weaknesses:

As the authors point out in the discussion, whether IL-1-mediated RhoA activation is specific to viral infection or regulates other RhoA-regulated processes is unclear. We would also require high-magnification images of the subcellular organization of the cytoskeleton to appreciate the effect of IL-1 stimulation.

Reviewer #2 (Public Review):

Summary:

In this study, Zheng et al investigated the role of inflammatory cytokines in protecting cells against SARS-CoV-2 infection. They demonstrate that soluble factors in the supernatants of TLR-stimulated THP1 cells reduce fusion events between HEK293 cells expressing SARS-CoV-2 S protein and the ACE2 receptor. Using qRT-PCR and ELISA, they demonstrate that IL-1 cytokines are (not surprisingly) upregulated by TLR treatment in THP1 cells. Further, they convincingly demonstrate that recombinant IL-1 cytokines are sufficient to reduce cell-to-cell fusion mediated by the S protein. Using chemical inhibitors and CRISPR knock-out of key IL-1 receptor signaling components in HEK293 cells, they demonstrate that components of the myddosome (MYD88, IRAK1/4, and TRAF6) are required for fusion inhibition, but that downstream canonical signaling (i.e., TAK1 and NFKB activation) is not required. Instead, they provide evidence that IL-1-dependent non-canonical activation of RhoA/Rock is important for this phenotype. Importantly, the authors demonstrate that expression of a constitutively active RhoA alone is sufficient to inhibit fusion and that chemical inhibition of Rock could reverse this inhibition. The authors followed up these in vitro experiments by examining the effects of IL-1 on SARS-COV-2 infection in vivo and they demonstrate that recombinant IL-1 can reduce viral burden and lung pathogenesis in a mouse model of infection. However, the contribution of the RhoA/Rock pathway and inhibition of fusion to IL-1-mediated control of SARS-CoV-2 infection in vivo remains unclear.

Strengths:

(1) The bioluminescence cell-cell fusion assay provides a robust quantitative method to examine cytokine effects on viral glycoprotein-mediated fusion.

(2) The study identifies a new mechanism by which IL-1 cytokines can limit virus infection.

(3) The authors tested IL-1 mediated inhibition of fusion induced by many different coronavirus S proteins and several SARS-CoV-2 strains.

Weaknesses:

(1) The qualitative assay demonstrating S2 cleavage and IL-1 mediated inhibition of this phenotype is extremely variable across the data figures. Sometimes it appears like S2 cleavage (S2') is reduced, while in other figures immunoblots show that total S2 protein is decreased. Based on the proposed model the expectation would be that S2 abundance would be rescued when cleavage is inhibited.

(2) The text referencing Figure 1H suggests that TLR-stimulated THP-1 cell supernatants "significantly" reduce syncytia, but image quantification and statistics are not provided to support this statement.

(3) The authors conclude that because IL-1 accumulates in TLR2-stimulated THP1 monocyte supernatants, this cytokine accounts for the ability of these supernatants to inhibit cell-cell fusion. However, they do not directly test whether IL-1 is required for the phenotype. Inhibition of the IL-1 receptor in supernatant-treated cells would help support their conclusion.

(4) Immunoblot analysis of IL-1 treated HEK293 cells suggests that this cytokine does not reduce the abundance of ACE2 or total S protein in cells. However, it is possible that IL-1 signaling reduces the abundance of these proteins on the cell surface, which would result in a similar inhibition of cell-cell fusion. The authors should confirm that IL-1 treatment of their cells does not change Ace2 or S protein on the cell surface.

(5) In Figure 5A, expression of constitutively active RhoA appears to have profound effects on how ACE2 runs by SDS-PAGE, suggesting that RhoA may have additional effects on ACE2 biology that might account for the decreased cell-cell fusion. This phenotype should be addressed in the text and explored in more detail.

(6) The experiments linking IL-1 mediated restriction of SARS-COV-2 fusion to the control of virus infection in vivo are incomplete. The reported data demonstrate that recombinant IL-1 can restrict virus replication in vivo, but they fall short of confirming that the in vitro mechanism described (reduced fusion) contributes to the control of SARS-CoV2 replication in vivo. A critical piece of data that is missing is the demonstration that the ROCK inhibitor phenocopies IL-1RA treatment of SARS-COV-2 infected mice (viral infection and pathology).